WHITEHAWK THERAPEUTICS, INC. Debt Conversion, Converted Instrument, Amount
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Debt Conversion, Converted Instrument, Amount of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2023-03-29
- WHITEHAWK THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2022-12-31 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2021-12-31 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2017-12-31 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2017-09-30 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- WHITEHAWK THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2021 was $9.13M.
- WHITEHAWK THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2017 was $13.45M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $0.00 10-K · filed 2023-03-29 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $9.13M 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $9.13M 10-Q · filed 2022-11-09 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $0.00 derived: sum of 2 quarters · filed 2019-03-07 | $0.00 derived: sum of 3 quarters · filed 2019-03-07 | $13.45M 10-K · filed 2019-03-07 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $13.45M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $13.45M 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | $13.45M 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |